A citation-based method for searching scientific literature

James M Cleary, Andrew J Aguirre, Geoffrey I Shapiro, Alan D D'Andrea. Mol Cell 2020
Times Cited: 43







List of co-cited articles
548 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
39

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
37

State-of-the-art strategies for targeting the DNA damage response in cancer.
Patrick G Pilié, Chad Tang, Gordon B Mills, Timothy A Yap. Nat Rev Clin Oncol 2019
315
27

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
23

PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
929
23

The DNA damage response: making it safe to play with knives.
Alberto Ciccia, Stephen J Elledge. Mol Cell 2010
20

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
Jessica S Brown, Brent O'Carrigan, Stephen P Jackson, Timothy A Yap. Cancer Discov 2017
267
18

ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response.
Andrew N Blackford, Stephen P Jackson. Mol Cell 2017
660
18

DNA Damage and Repair Biomarkers of Immunotherapy Response.
Kent W Mouw, Michael S Goldberg, Panagiotis A Konstantinopoulos, Alan D D'Andrea. Cancer Discov 2017
283
16


Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.
Raphael Ceccaldi, Jessica C Liu, Ravindra Amunugama, Ildiko Hajdu, Benjamin Primack, Mark I R Petalcorin, Kevin W O'Connor, Panagiotis A Konstantinopoulos, Stephen J Elledge, Simon J Boulton,[...]. Nature 2015
394
16

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh,[...]. N Engl J Med 2019
633
16

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
853
16

Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, David C Wedge, Samuel A J R Aparicio, Sam Behjati, Andrew V Biankin, Graham R Bignell, Niccolò Bolli, Ake Borg, Anne-Lise Børresen-Dale,[...]. Nature 2013
13

The DNA-damage response in human biology and disease.
Stephen P Jackson, Jiri Bartek. Nature 2009
13

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
13

Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
Alice Bradbury, Sally Hall, Nicola Curtin, Yvette Drew. Pharmacol Ther 2020
41
14

Mechanisms of PARP inhibitor sensitivity and resistance.
Alan D D'Andrea. DNA Repair (Amst) 2018
156
13

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Junko Murai, Shar-yin N Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier. Cancer Res 2012
13

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
13

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.
Constantia Pantelidou, Olmo Sonzogni, Mateus De Oliveria Taveira, Anita K Mehta, Aditi Kothari, Dan Wang, Tanvi Visal, Michelle K Li, Jocelin Pinto, Jessica A Castrillon,[...]. Cancer Discov 2019
171
13

Non-homologous DNA end joining and alternative pathways to double-strand break repair.
Howard H Y Chang, Nicholas R Pannunzio, Noritaka Adachi, Michael R Lieber. Nat Rev Mol Cell Biol 2017
564
13

First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
Timothy A Yap, David S P Tan, Angelika Terbuch, Reece Caldwell, Christina Guo, Boon Cher Goh, Valerie Heong, Noor R Md Haris, Saira Bashir, Yvette Drew,[...]. Cancer Discov 2021
26
19

Targeting the replication stress response in cancer.
Josep V Forment, Mark J O'Connor. Pharmacol Ther 2018
74
11

The plasticity of DNA replication forks in response to clinically relevant genotoxic stress.
Matteo Berti, David Cortez, Massimo Lopes. Nat Rev Mol Cell Biol 2020
45
11

DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells.
Hiro Sato, Atsuko Niimi, Takaaki Yasuhara, Tiara Bunga Mayang Permata, Yoshihiko Hagiwara, Mayu Isono, Endang Nuryadi, Ryota Sekine, Takahiro Oike, Sangeeta Kakoti,[...]. Nat Commun 2017
231
11

A Genetic Map of the Response to DNA Damage in Human Cells.
Michele Olivieri, Tiffany Cho, Alejandro Álvarez-Quilón, Kejiao Li, Matthew J Schellenberg, Michal Zimmermann, Nicole Hustedt, Silvia Emma Rossi, Salomé Adam, Henrique Melo,[...]. Cell 2020
90
11

Causes and consequences of replication stress.
Michelle K Zeman, Karlene A Cimprich. Nat Cell Biol 2014
967
11

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Stephanie A Yazinski, Valentine Comaills, Rémi Buisson, Marie-Michelle Genois, Hai Dang Nguyen, Chu Kwen Ho, Tanya Todorova Kwan, Robert Morris, Sam Lauffer, André Nussenzweig,[...]. Genes Dev 2017
170
11

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Kalindi Parmar, Bose S Kochupurakkal, Jean-Bernard Lazaro, Zhigang C Wang, Sangeetha Palakurthi, Paul T Kirschmeier, Chunyu Yang, Larissa A Sambel, Anniina Färkkilä, Elizaveta Reznichenko,[...]. Clin Cancer Res 2019
51
11

53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks.
Samuel F Bunting, Elsa Callén, Nancy Wong, Hua-Tang Chen, Federica Polato, Amanda Gunn, Anne Bothmer, Niklas Feldhahn, Oscar Fernandez-Capetillo, Liu Cao,[...]. Cell 2010
11

The shieldin complex mediates 53BP1-dependent DNA repair.
Sylvie M Noordermeer, Salomé Adam, Dheva Setiaputra, Marco Barazas, Stephen J Pettitt, Alexanda K Ling, Michele Olivieri, Alejandro Álvarez-Quilón, Nathalie Moatti, Michal Zimmermann,[...]. Nature 2018
222
11

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Kyle C Strickland, Brooke E Howitt, Sachet A Shukla, Scott Rodig, Lauren L Ritterhouse, Joyce F Liu, Judy E Garber, Dipanjan Chowdhury, Catherine J Wu, Alan D D'Andrea,[...]. Oncotarget 2016
328
11

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
11

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Shiping Jiao, Weiya Xia, Hirohito Yamaguchi, Yongkun Wei, Mei-Kuang Chen, Jung-Mao Hsu, Jennifer L Hsu, Wen-Hsuan Yu, Yi Du, Heng-Huan Lee,[...]. Clin Cancer Res 2017
387
11

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
752
11

Therapeutic opportunities within the DNA damage response.
Laurence H Pearl, Amanda C Schierz, Simon E Ward, Bissan Al-Lazikani, Frances M G Pearl. Nat Rev Cancer 2015
280
11

Homologous recombination and the repair of DNA double-strand breaks.
William Douglass Wright, Shanaya Shital Shah, Wolf-Dietrich Heyer. J Biol Chem 2018
222
11

Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.
Theo A Knijnenburg, Linghua Wang, Michael T Zimmermann, Nyasha Chambwe, Galen F Gao, Andrew D Cherniack, Huihui Fan, Hui Shen, Gregory P Way, Casey S Greene,[...]. Cell Rep 2018
315
9

Nucleotide excision repair in humans.
Graciela Spivak. DNA Repair (Amst) 2015
159
9

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
Jacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, Paul W G Wijnhoven, Valeria Follia, Neil James, Paul M Farrington, Ankur Karmokar, Sophie E Willis, Jonathan Cairns,[...]. Nat Commun 2019
61
9


DNA double-strand break repair pathway choice is directed by distinct MRE11 nuclease activities.
Atsushi Shibata, Davide Moiani, Andrew S Arvai, Jefferson Perry, Shane M Harding, Marie-Michelle Genois, Ranjan Maity, Sari van Rossum-Fikkert, Aryandi Kertokalio, Filippo Romoli,[...]. Mol Cell 2014
332
9

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Marta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, Sara Gutiérrez-Enríquez, Mandy Ducy, Yasir Hussein Ibrahim, Albert Gris-Oliver, Benedetta Pellegrino, Alejandra Bruna, Marta Guzmán,[...]. EMBO Mol Med 2018
78
9

BRCAness revisited.
Christopher J Lord, Alan Ashworth. Nat Rev Cancer 2016
585
9

A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
Paz Polak, Jaegil Kim, Lior Z Braunstein, Rosa Karlic, Nicholas J Haradhavala, Grace Tiao, Daniel Rosebrock, Dimitri Livitz, Kirsten Kübler, Kent W Mouw,[...]. Nat Genet 2017
228
9

Clustered DNA Double-Strand Breaks: Biological Effects and Relevance to Cancer Radiotherapy.
Jac A Nickoloff, Neelam Sharma, Lynn Taylor. Genes (Basel) 2020
48
9



Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Timothy A Yap, Brent O'Carrigan, Marina S Penney, Joline S Lim, Jessica S Brown, Maria J de Miguel Luken, Nina Tunariu, Raquel Perez-Lopez, Daniel Nava Rodrigues, Ruth Riisnaes,[...]. J Clin Oncol 2020
41
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.